ADMA Biologics Inc (NASDAQ:ADMA – Get Free Report) Director Lawrence Guiheen sold 10,000 shares of the company’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $13.92, for a total transaction of $139,200.00. Following the completion of the transaction, the director owned 63,599 shares in the company, valued at approximately $885,298.08. This trade represents a 13.59% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
ADMA Biologics Stock Down 1.6%
Shares of ADMA opened at $13.46 on Tuesday. The firm has a market cap of $2.99 billion, a P/E ratio of 17.48 and a beta of 0.65. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.25 and a current ratio of 6.04. ADMA Biologics Inc has a 52 week low of $7.21 and a 52 week high of $20.46. The firm’s 50-day simple moving average is $10.65 and its 200 day simple moving average is $10.77.
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.03. ADMA Biologics had a net margin of 35.14% and a return on equity of 42.56%. The firm had revenue of $141.10 million during the quarter, compared to the consensus estimate of $138.11 million. During the same period last year, the business posted $0.15 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. On average, analysts forecast that ADMA Biologics Inc will post 0.82 earnings per share for the current year.
Wall Street Analyst Weigh In
Several analysts recently weighed in on ADMA shares. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Mizuho set a $18.00 price objective on ADMA Biologics in a report on Thursday, November 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Finally, Cantor Fitzgerald increased their price objective on ADMA Biologics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.50.
Read Our Latest Research Report on ADMA Biologics
Institutional Trading of ADMA Biologics
A number of institutional investors have recently bought and sold shares of ADMA. NorthCrest Asset Manangement LLC grew its position in shares of ADMA Biologics by 8.4% during the 3rd quarter. NorthCrest Asset Manangement LLC now owns 15,952 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,234 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of ADMA Biologics by 4.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 32,087 shares of the biotechnology company’s stock valued at $319,000 after buying an additional 1,316 shares in the last quarter. Pinnacle Wealth Planning Services Inc. raised its position in shares of ADMA Biologics by 33.1% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 5,721 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 1,422 shares in the last quarter. CenterBook Partners LP raised its position in shares of ADMA Biologics by 1.8% in the third quarter. CenterBook Partners LP now owns 81,607 shares of the biotechnology company’s stock valued at $819,000 after buying an additional 1,432 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of ADMA Biologics by 0.4% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 395,356 shares of the biotechnology company’s stock valued at $3,309,000 after buying an additional 1,705 shares during the period. Institutional investors own 75.68% of the company’s stock.
About ADMA Biologics
ADMA Biologics is a biopharmaceutical company that develops, manufactures and markets plasma-derived therapies for people with immune deficiencies and certain infectious diseases. Its products include BIVIGAM and ASCENIV, intravenous immune globulin therapies used to treat primary humoral immunodeficiency, and Nabi-HB, an immune globulin used for hepatitis B prevention in specific clinical settings. The company collects human plasma through its U.S. donor centers and processes it into therapies at its manufacturing facility in Boca Raton, Florida.
Further Reading
- Five stocks we like better than ADMA Biologics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
